Domain Therapeutics, a strategic partner of pharmaceutical companies, is aimed at discovering new drug candidates targeting G-Protein Coupled Receptors (GPCRs) in all major therapeutic fields.
GPCRs, by representing one third of current drug's targets, consitute one of the most validated therapeutic target classes. Whereas current GPCR drugs target about 50 receptors, there remains an untapped potential of approximately 350 GPCRs to be further investigated. These 350 members contain validated targets as well as orphan receptors.
Domain Therapeutics operates its GPCR-dedicated platforms to run drug discovery programs from hit generation to preclinical candidates and offers its partners to collaborate on drug discovery projects or to license patented drug candidates.
To date, Domain Therapeutics has signed research and/or collaboration agreements with: Takeda, Merck Serono, Prexton Therapeutics and ONO Pharmaceutical. The Company has generated programs in a wide range of major therapeutic fields including neurological, neuropsychiatric diseases, metabolic disorders, inflammation and oncology.
Domain will attend the BIOJapan 2015 Convention, on October 15-17, 2015 in Pacifico Yokohama
Ismet Dorange, Head of Domain’s Medicinal Chemistry Department, served as guest editor of the thematic issue “New Paradigms in GPCR Drug Discovery” published in Current Topics in Medicinal Chemistry
Domain will attend the RESI Conference, on September 16, 2015 in Boston
Domain Therapeutics launches Specific Purpose Vehicle Kaldi Pharma to harness the potential of its adenosine programsDownload the PDF file to learn more